Effects of Tofacitinib on Bone Marrow Edema, Synovitis, and Erosive Damage in Methotrexate-Naive Patients with Early Active Rheumatoid Arthritis (Duration ≤2 Years): Results of an Exploratory Phase 2 MRI Study.

被引：0
|
作者：
Conaghan, Philip G. [1 ,2 ]
Ostergaard, M. [3 ]
Wu, C. [4 ]
van der Heijde, D. [5 ]
Irazoque-Palazuelos, F. [6 ]
Hrycaj, P. [7 ]
Xie, Z. [8 ]
Zhang, R. [8 ]
Wyman, B. T. [8 ]
Bradley, J. D. [8 ]
Soma, K. [8 ]
Wilkinson, B. [8 ]
机构：
[1] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England
[2] Chapel Allerton Hosp, NIHR Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England
[3] Copenhagen Ctr Arthrit Res, Glostrup, Denmark
[4] BioClinca Inc, Newark, CA USA
[5] Leiden Univ, Med Ctr, Leiden, Netherlands
[6] Hosp Angeles Mocel, Serv Reumatol, Mexico City, DF, Mexico
[7] Poznan Univ Med Sci, Poznan, Poland
[8] Pfizer Inc, Groton, CT 06340 USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2014年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1181
引用
收藏
页码：S519 / S520
页数：2
相关论文
共 38 条
  • [1] Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques
    Conaghan, Philip G.
    Ostergaard, Mikkel
    Bowes, Michael A.
    Wu, Chunying
    Fuerst, Thomas
    van der Heijde, Desiree
    Irazoque-Palazuelos, Fedra
    Soto-Raices, Oscar
    Hrycaj, Pawel
    Xie, Zhiyong
    Zhang, Richard
    Wyman, Bradley T.
    Bradley, John D.
    Soma, Koshika
    Wilkinson, Bethanie
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (06) : 1024 - 1033
  • [2] EFFECTS OF TOFACITINIB ON MRI ENDPOINTS IN METHOTREXATE-NAIVE EARLY RHEUMATOID ARTHRITIS: A PHASE 2 MRI STUDY WITH SEMI-QUANTITATIVE AND QUANTITATIVE ENDPOINTS
    Conaghan, P. G.
    Ostergaard, M.
    Bowes, M. A.
    Wu, C.
    Fuerst, T.
    van der Heijde, D.
    Hrycaj, P.
    Xie, Z.
    Zhang, R.
    Wyman, B. T.
    Bradley, J.
    Soma, K.
    Wilkinson, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 738 - 738
  • [3] RELATIONSHIP BETWEEN DIFFERENT CLINICAL MEASUREMENTS AND PATIENT-REPORTED OUTCOMES: RESULTS FROM A PHASE 3 STUDY OF TOFACITINIB OR METHOTREXATE IN METHOTREXATE-NAIVE PATIENTS WITH RHEUMATOID ARTHRITIS
    Fleischmann, R.
    Strand, V.
    Wilkinson, B.
    Kwok, K.
    Bananis, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 259 - 260
  • [4] EFFECTS OF TOFACITINIB MONOTHERAPY VERSUS METHOTREXATE ON PATIENT-REPORTED OUTCOMES IN THE 2-YEAR PHASE 3 ORAL START TRIAL IN METHOTREXATE-NAIVE PATIENTS WITH RHEUMATOID ARTHRITIS
    Alten, R.
    Strand, V.
    Fleischmann, R.
    Koncz, T.
    Zwillich, S.
    Bradley, J.
    Gruben, D.
    Wilkinson, B.
    Krishnaswami, S.
    Wallenstein, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 118 - 119
  • [5] TOFACITINIB MONOTHERAPY IS EFFECTIVE IN METHOTREXATE-NAIVE PATIENTS WITH DISEASE DURATION LESS THAN 6 MONTHS: A POST-HOC ANALYSIS OF EARLY RHEUMATOID ARTHRITIS SUBJECTS IN A PHASE 3 TRIAL
    Huizinga, T. W. J.
    Fleischmann, R.
    van Vollenhoven, R.
    Gruben, D.
    Wilkinson, B.
    Koncz, T.
    Bradley, J.
    Zwillich, S. H.
    Benda, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 241 - 241
  • [6] Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial
    Burmester, Gerd R.
    Rigby, William F.
    van Vollenhoven, Ronald F.
    Kay, Jonathan
    Rubbert-Roth, Andrea
    Blanco, Ricardo
    Kadva, Alysha
    Dimonaco, Sophie
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (07) : 1279 - 1284
  • [7] Tocilizumab Combination Therapy or Monotherapy or Methotrexate Monotherapy in Methotrexate-Naive Patients with Early Rheumatoid Arthritis: 2-Year Clinical and Radiographic Results from a Randomized, Placebo-Controlled Trial.
    Burmester, Gerd
    Rigby, William
    van Vollenhoven, Ronald F.
    Kay, Jonathan
    Rubbert-Roth, Andrea
    Blanco, Ricardo
    Kelman, Ariella
    Dimonaco, Sophie
    Mitchell, Nina
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S811 - S812
  • [8] Golimumab in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results Through 2 Years of the GO-FORWARD Study Extension
    Keystone, Edward C.
    Genovese, Mark C.
    Hall, Stephen
    Miranda, Pedro C.
    Bae, Sang-Cheol
    Palmer, William
    Wu, Zhong
    Xu, Stephen
    Hsia, Elizabeth C.
    JOURNAL OF RHEUMATOLOGY, 2013, 40 (07) : 1097 - 1103
  • [9] Tofacitinib, an Oral Janus Kinase Inhibitor, in Combination with Methotrexate Reduced the Progression of Structural Damage in Patients with Rheumatoid Arthritis: Year 2 Efficacy and Safety Results From a 24-Month Phase 3 Study
    van der Heijde, D.
    Tanaka, Y.
    Fleischmann, R. M.
    Keystone, E.
    Kremer, J. M.
    Zerbini, C.
    Cardiel, M. H.
    Cohen, S. B.
    Nash, P. T.
    Song, Y.
    Tegzova, D.
    Wyman, B.
    Gruben, D.
    Benda, B.
    Wallenstein, G.
    Krishnaswami, S.
    Zwillich, S. H.
    Bradley, J.
    Connell, C. A.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S546 - S547
  • [10] Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials
    Wallenstein, G. V.
    Kanik, K. S.
    Wilkinson, B.
    Cohen, S.
    Cutolo, M.
    Fleischmann, R.
    Genovese, M. C.
    Gomez Reino, J.
    Gruben, D.
    Kremer, J.
    Krishnaswami, S.
    Lee, E. B.
    Pascual-Ramos, V.
    Strand, V.
    Zwillich, S. H.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (03) : 430 - 442
1234